Floatz logo

Brentuximab Vedotin

Primary Cutaneous Anaplastic Large Cell Lymphoma

John Reneauantibody_drug_conjugatePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Primary Cutaneous Anaplastic Large Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Bexarotene
Millennium Pharmaceuticals, Inc.
Phase 3BB
METHOTREXATE
Millennium Pharmaceuticals, Inc.
Phase 3BB
cc-5013
John Reneau
Phase 2B
Pralatrexate
Acrotech Biopharma Inc.
Phase 1CC
Bendamustine
UNC Lineberger Comprehensive Cancer Center
Phase 1CC

View all 9 →

Same molecule, other indications

Brentuximab Vedotin is also rated in:

T-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
anaplastic large cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →